AhmannAJCapehornMCharpentierGDottaFHenkelELingvayIet alEfficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial
PMID: 29249689 | doi:10.1016/j.cmet.2017.11.002 Tang QQ et al
and advisory boards for Altimmune,Inc., Arrowhead Pharmaceuticals, Inc., BioAge, Biolinq Incorporated,Caribou Biosciences, Inc., CinFina Pharma, Inc., Covidien LP, Cowenand Company, LLC, Currax Pharmaceuticals, LLC, EPG CommunicationHoldings Ltd., Form Health, Inc., Fractyl Health, Inc., Lilly USA, LLC, LNutra, Inc., Mediflix Inc., NeuroBo Pharmaceuticals, Inc., NeurocrineBiosciences, Inc., NodThera Limited, Nutrisystem, OptumRx, Inc., PainScript Corporation, Palatin Technologies, Inc., Pursuit By You, RedesignHealth Inc., ReShape Lifesciences Inc., Riverview School, Roman HealthVentures Inc., Scholar Rock, Inc., Terns, Inc., Verily Life Sciences LLC,Veru Inc., Vida Health, Inc., Wave Life Sciences, Xeno Biosciences andZyversa Therapeutics, Inc
While no major safety flags have emerged from either the scientific literature or widespread anecdotal use, the absence of large-scale human data means users should proceed carefullyespecially if considering high doses or long-term use
A thorough medical evaluation is necessary to determine if it is appropriate for you
tBHQ attenuates podocyte injury in diabetic nephropathy by inhibiting NADPH oxidase-derived ROS generation via the Nrf2/HO-1 signalling pathway
